Omega Fund Management’s Immunocore IMCR Stock Holding History

Omega Fund Management’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-51,535	Closed	-$1.92M	–	21
2022 Q2	$1.92M	Hold	51,535	–	–	0.61%	18
2022 Q1	$1.54M	Hold	51,535	–	–	0.32%	22
2021 Q4	$1.76M	Hold	51,535	–	–	0.25%	22
2021 Q3	$1.91M	Hold	51,535	–	–	0.21%	24
2021 Q2	$2.01M	Hold	51,535	–	–	0.23%	22
2021 Q1	$2.19M	Buy	+51,535	New	+$2.29M	0.21%	23

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Omega Fund Management's IMCR Position: Q3 2022 in Review

Omega Fund Management sold out of Immunocore (IMCR) in Q3 2022, closing a stake of 51,535 shares — an estimated $1.92M sold.

Omega Fund Management first reported a position in IMCR in Q1 2021 and held it in 6 quarters. The position peaked at $2.19M in Q1 2021. 86 funds tracked by Wall St. Rank hold IMCR as of Q3 2022.

Omega Fund Management reported no remaining Immunocore position as of Q3 2022 after selling out during the quarter.
Omega Fund Management sold 51,535 Immunocore shares in Q3 2022, an estimated $1.92M.
Omega Fund Management first reported a position in Immunocore in Q1 2021 and held it in 6 quarters.
Omega Fund Management's Immunocore position peaked at $2.19M in Q1 2021.
86 funds tracked by Wall St. Rank held Immunocore as of Q3 2022.

Based on Omega Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.